Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Reproductive Science Center
Age
21–43
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Are willing to participate in this clinical study
Are able to comprehend and give informed consent for participation in this study
Have read, understood and signed an informed consent form
Have been unable to achieve pregnancy after trying for 1 year or greater and who have unilateral or bilateral hydrosalpinges as evidenced by laparoscopy or ultrasound or HSG
Have a Day #3 serum FSH\<10, and Day #3 Estradiol\<80
Recipient women undergoing a ovum donor cycle the donor must have a Day 3 serum FSH \< 10 and Day 3 Estradiol \< 80
Have an antral follicle count 10 or greater for both ovaries combined, if women using ovum donor (follicle count) will be based on eligible donor
Have a desire to receive treatment for their HS
Are willing to undergo a hysterosalpingogram (HSG) 3 months after ADIANA placement to confirm proximal tubal occlusion
You may not be if
Active or recent upper or lower pelvic infection
Known hypersensitivity to nickel as confirmed by skin test
Known allergy to contrast media
Pregnancy or suspected pregnancy
Delivery or termination of pregnancy less than six weeks prior to Adiana placements
BMI \> 35
Abnormal pap smear (CIN2 or greater abnormality) within the past year
Pelvic malignancy
Severely retroverted uterus
Evidence of intrauterine abnormalities such as submucous fibroids, polyps, intrauterine adhesions or presence of a uterine septum
Abnormal Clomid Challenge Test or abnormal lab values on Day #3 serum FSH and Estradiol
Antral follicle count less than 10 (both ovaries combined)
Poor general or gynecologic health
Inability or refusal to provide informed consent
Clareo Health | Use of Adiana Tubal Occlusive Devices in Women With Hydrosalpinx Prior to In Vitro Fertilization
